Clinical Trial Update: Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the safety, efficacy, and pharmacokinetics of regorafenib in combination with pemetrexed and cisplatin in nonsquamous non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• CISPLATIN (cisplatin)
• Stivarga (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Small Cell Lung Carcinoma | Phase 1 | Status: TERMINATED